Hoda Kotb Menopause: How the Media Narrative Shifted

Why a Morning-Show Host Talking About Menopause Is Actually Significant

Morning television reaches tens of millions of women every day. For decades, the format treated menopause the way most clinical encounters did: briefly, awkwardly, and with a pivot toward something more comfortable. Hoda Kotb changed that pattern. When she began speaking openly about her own midlife experience on the Today show, she brought a conversation that women were already having in private into a broadcast format watched by an audience that skews heavily toward women aged 45 to 65.

That audience is the exact cohort the menopause transition hits hardest. Approximately 1.3 million U.S. Women reach menopause each year, and the average age of natural menopause in the United States is 51.4 years, as documented by the Study of Women's Health Across the Nation (SWAN). The women watching Hoda at 7 a.m. Were, statistically, either in perimenopause, at menopause, or postmenopausal.

The Silence That Preceded Her

Before roughly 2022, menopause was discussed on mainstream television almost exclusively in one of two ways: as a punchline (hot flash jokes directed at older women characters in sitcoms) or as a clinical explainer segment lasting under four minutes, usually cued by a pharmaceutical advertisement. Neither format served the woman sitting at home wondering whether her vasomotor symptoms were severe enough to treat.

The result of that silence was measurable. A 2022 survey published in Menopause found that fewer than 25% of symptomatic women received any menopause-specific treatment, despite the fact that up to 80% of women experience vasomotor symptoms such as hot flashes and night sweats during the transition. The gap between symptom burden and treatment access is not primarily a supply problem. Clinicians exist. Treatments exist. The gap is partly a conversation problem: women were not hearing that treatment was an option, and many felt that suffering through symptoms was simply what middle age looked like.

What Hoda Actually Said

Kotb did not deliver a clinical lecture. She spoke the way women speak to each other, naming symptoms (disrupted sleep, mood changes, the feeling that her body was doing something she did not recognize), describing her own process of seeking information, and expressing relief at finding that what she was experiencing had a name and a set of options. That register, personal and unhurried, is precisely what clinical messaging has historically failed to replicate.

She also modeled help-seeking behavior at a life stage when women frequently deprioritize their own health. Research published in JAMA Internal Medicine found that women in midlife are significantly less likely than men to seek care for new symptoms, in part because they have been socialized to frame those symptoms as normal aging rather than as treatable conditions.

What the Physiology Actually Looks Like at This Life Stage

Understanding why Kotb's conversation resonated requires understanding what the menopause transition actually does to a woman's body. This is not a single event. It is a years-long hormonal recalibration that affects nearly every organ system.

The Hormonal Architecture of the Transition

Menopause is defined clinically as 12 consecutive months without a menstrual period, confirmed retrospectively. The ovaries' follicular reserve depletes progressively, driving estradiol levels from roughly 50 to 400 pg/mL during reproductive years down to below 20 pg/mL postmenopause. Follicle-stimulating hormone (FSH) rises sharply as the pituitary attempts to compensate, often reaching levels above 40 mIU/mL.

Perimenopause, the transition period preceding that 12-month mark, can begin as many as 10 years before the final menstrual period. During perimenopause, estradiol levels fluctuate erratically, which is why symptoms can appear while cycles are still occurring. This erratic pattern, not simply "low estrogen," drives much of the vasomotor and mood symptom burden.

Symptoms Women in Their 50s Actually Experience

The symptom picture is broader than the hot-flash shorthand suggests:

• Vasomotor symptoms: hot flashes and night sweats, affecting up to 80% of women, peaking in the late perimenopause to early postmenopause window
• Sleep disruption: often secondary to night sweats but also driven by independent effects of estrogen and progesterone loss on sleep architecture
• Genitourinary syndrome of menopause (GSM): vaginal dryness, urinary urgency, and dyspareunia, affecting approximately 50% of postmenopausal women but discussed far less openly than vasomotor symptoms
• Cognitive changes: subjective memory complaints are common in perimenopause; the SWAN study documented measurable changes in processing speed and verbal memory during the transition
• Mood changes: risk of depressive symptoms increases during perimenopause even in women with no prior psychiatric history, per data from the Harvard Study of Moods and Cycles
• Metabolic shift: loss of estrogen accelerates visceral fat accumulation, unfavorable lipid shifts, and insulin resistance

Women aged 58 to 60, roughly where Kotb was during her most public disclosures, are typically postmenopausal. Their estrogen levels have been low for several years, meaning GSM and metabolic consequences are often more prominent than acute vasomotor symptoms at this point, though vasomotor symptoms can persist for a median of 7.4 years past the final menstrual period according to the SWAN study.

The Evidence Base for Menopause Treatment: What Options Exist

Treating menopause symptoms is not guesswork. A structured clinical framework exists, and the evidence base has grown substantially since the initial misinterpretation of the 2002 Women's Health Initiative findings caused a generation of women to be undertreated.

Hormone Therapy: The Evidence Has Been Reappraised

The 2002 Women's Health Initiative (WHI) trial initially led to widespread discontinuation of hormone therapy. The subsequent reanalysis, and the 2022 Hormone Therapy Position Statement of The Menopause Society, clarified the picture substantially. For healthy women under 60 or within 10 years of menopause onset, the benefit-risk ratio for hormone therapy to treat bothersome vasomotor symptoms is favorable.

The Menopause Society's 2022 position statement states directly: "Hormone therapy remains the most effective treatment for vasomotor symptoms and the genitourinary syndrome of menopause and has been shown to prevent bone loss and fracture."

Key clinical distinctions that the WHI reanalysis clarified:

• Age and timing matter: Women who initiate hormone therapy before age 60 or within 10 years of menopause have a different cardiovascular risk profile than older women initiating therapy, per reanalysis published in Climacteric
• Route matters: Transdermal estrogen does not carry the same venous thromboembolism risk as oral conjugated equine estrogen; a 2015 BMJ study found no increased VTE risk with transdermal estradiol
• Progestogen type matters: Micronized progesterone (Prometrium) may carry a more favorable breast and cardiovascular safety profile than synthetic progestins, per the E3N French cohort study

Non-Hormonal Options

For women who cannot or choose not to use hormone therapy, several evidence-supported options exist:

• Fezolinetant (Veozah): A neurokinin 3 receptor antagonist approved by the FDA in May 2023 specifically for moderate-to-severe vasomotor symptoms. This is the first non-hormonal, non-antidepressant option approved for this indication.
• Low-dose paroxetine 7.5 mg (Brisdelle): FDA-approved for vasomotor symptoms; SSRIs as a class reduce hot flash frequency by approximately 50-60% in clinical trials
• Cognitive behavioral therapy (CBT): A 2021 Cochrane review found CBT reduced the problem rating of hot flashes more than control conditions, though it does not reduce objective frequency as much as pharmacotherapy

Local Therapy for GSM

Genitourinary syndrome of menopause often goes unaddressed because women feel uncomfortable raising it. Local vaginal estrogen (cream, ring, or tablet) delivers estrogen directly to the vaginal epithelium with minimal systemic absorption and is safe even in most women with a history of hormone-sensitive cancers, per ACOG guidance. Ospemifene, an oral selective estrogen receptor modulator, is also FDA-approved for dyspareunia from GSM.

Why the Media Narrative Around Menopause Had Been So Distorted

The coverage gap was not accidental. Several structural forces kept menopause off mainstream media's agenda for decades, and Kotb's visibility disrupts each of them.

Women Over 50 Were Treated as a Secondary Audience

Advertising logic historically prized the 18-to-49 demographic. Women over 50, despite controlling approximately $15 trillion in U.S. Consumer spending, were systematically deprioritized in both programming and health coverage. Menopause, a condition affecting every woman who lives past her 40s, received coverage proportional to its perceived demographic irrelevance, which meant almost none.

The WHI Fallout Created a Clinical and Media Vacuum

The 2002 WHI results created a vacuum. Physicians stopped prescribing hormone therapy. Media stopped covering it as a treatment option. Women were left with a message that amounted to "endure it." The narrative did not recover even as the evidence base was reappraised, because nuanced reanalysis rarely generates the same headlines as a dramatic initial finding.

Shame and the Language of "Natural Aging"

Menopause was framed as something to hide rather than something to treat. The phrase "natural aging" did double duty: medically accurate in the sense that menopause is a normal biological process, but functionally a reason not to seek care. Hot flashes, disrupted sleep, and mood changes were coded as weakness or embarrassment rather than as symptoms with a pathophysiology and a treatment pathway.

Kotb's willingness to name her experience without visible shame recoded that framing in real time, in front of an audience that had been absorbing the shame-coded version for decades.

What This Means for the Woman Watching at Home

The clinical stakes of the media conversation are real. When women hear public figures describe symptoms they recognize, care-seeking increases. A 2023 analysis found that internet searches for "menopause treatment" spiked significantly during and after high-profile celebrity disclosures. That search behavior translates, for some proportion of women, into clinical appointments they would not otherwise have made.

The Women Most Likely to Benefit From Improved Awareness

The treatment access gap is not evenly distributed. Black women experience more severe vasomotor symptoms and for longer duration than white women, per SWAN data, yet are less likely to receive hormone therapy. Hispanic and Asian women face both language barriers and additional cultural stigma around discussing menopause. Rural women face provider shortages; only about 6,000 clinicians in the U.S. Have specific menopause training. A media conversation that normalizes the topic does not close those gaps on its own, but it shifts the baseline.

The Limits of Celebrity Visibility

Visibility is not the same as clinical guidance. Kotb's experience is her experience. Her symptom picture, her risk profile, her treatment choices (which she has not publicly specified in detail) are hers. Women watching should hear the conversation as an invitation to seek care, not as a template for what their own treatment should look like. The appropriate next step is a clinician who takes a full personal and family history, including cardiovascular, bone density, and breast cancer risk factors, before recommending any treatment pathway.

The Menopause Society's 2022 position statement is explicit on individualization: treatment decisions should be made on a case-by-case basis, weighing each woman's symptom severity, personal health history, preferences, and values.

Life-Stage Breakdown: Menopause Across the Reproductive Continuum

Reproductive Years and Early Perimenopause (Approximately Ages 40 to 47)

Perimenopause can begin in the early 40s with subtle changes: cycles becoming slightly shorter or more variable, premenstrual symptoms intensifying, early sleep disruption. Many women in this stage are still focused on fertility or in the postpartum period; ACOG recommends that all women be counseled about the perimenopause transition beginning in their early 40s.

Late Perimenopause (Approximately Ages 47 to 52)

Cycles become irregular, skipping months. Vasomotor symptoms are often at their most intense in this window. For women still cycling, hormonal contraception (including low-dose combined oral contraceptives or the levonorgestrel IUD) can simultaneously provide cycle control, contraception (still needed until menopause is confirmed), and some symptom relief.

Early Postmenopause (Years 1 to 5 After Final Menstrual Period)

This is the window in which hormone therapy initiation carries the most favorable benefit-risk profile for cardiovascular health, per the timing hypothesis. Bone loss accelerates sharply in the first two years postmenopause; women lose approximately 2% of bone mineral density per year in the first five years following menopause.

Late Postmenopause (More Than 5 Years After Final Menstrual Period)

Kotb's likely life-stage at time of her most public disclosures. Vasomotor symptoms may persist but often moderate. GSM becomes the dominant quality-of-life issue for many women. Cardiovascular and bone health are central clinical concerns. Initiating systemic hormone therapy for the first time after age 60 or more than 10 years past menopause carries a less favorable risk profile and requires individual risk assessment.

The Evidence Gap: What We Do Not Know About Women Like Hoda

Women over 55, Black women, Hispanic women, and women with complex medical histories were underrepresented in the foundational menopause hormone therapy trials. The WHI enrolled predominantly white women with a mean age of 63, already several years past the timing window now considered optimal. This evidence gap is acknowledged by The Menopause Society and remains an active area of research.

Kotb is a Black woman. The data most relevant to her risk profile, symptom burden, and treatment response is thinner than the data for white women of similar age. SWAN data shows Black women report more frequent and more severe vasomotor symptoms, but clinical trial representation has not matched that prevalence. Any clinician caring for Black women in the menopause transition should account for this gap explicitly, not assume that population-average data derived from predominantly white samples applies uniformly.

What a Thoughtful Menopause Protocol Actually Includes

A complete menopause evaluation is not a single prescription. It involves assessment across several domains:

• Symptom inventory: Validated tools such as the Menopause Rating Scale or the Greene Climacteric Scale quantify symptom burden and track response to treatment
• Cardiovascular risk: Blood pressure, lipid panel, fasting glucose, body weight, smoking history
• Bone health: Dual-energy X-ray absorptiometry (DEXA) scan; ACOG recommends baseline DEXA at age 65 in average-risk women, earlier in those with risk factors
• Breast health: Current mammography, personal and family history of breast cancer, BRCA status if indicated
• Reproductive history: Age at menarche, parity, prior oral contraceptive use, history of conditions such as endometriosis, PCOS, or premature ovarian insufficiency, all of which can affect the menopause experience and treatment choices
• Sexual health: Direct questions about libido, arousal, lubrication, and dyspareunia; hypoactive sexual desire disorder affects approximately 10% of premenopausal and a higher proportion of postmenopausal women and is treatable
• Mental health: Depression and anxiety screening; perimenopause is a period of elevated psychiatric vulnerability

This is the protocol Kotb's conversation has, indirectly, made it easier for women to ask about. Getting to that appointment is the first step. Knowing what to ask for is the second.